文献速递妇科

子宫子宫内膜间质肿瘤:流行病学、病理与生物学特征、治疗选择及临床结局

Endometrial stromal tumors of the uterus: Epidemiology, pathological and biological features, treatment options and clinical outcomes.
PubMed 文献 · Gynecol Oncol · 2023-02-24

子宫内膜间质肿瘤(EST)是罕见的子宫间叶源性肿瘤,年发病率约0.30/10万女性,多见于围绝经期或绝经后女性。低级别子宫内膜间质肉瘤(LG-ESS)以JAZF1-SUZ12重排为最常见遗传学改变,高级别子宫内膜间质肉瘤(HG-ESS)以t(10;17)(q23,p13)易位和BCOR基因异常为两大亚型特征,未分化子宫肉瘤(UUS)无特异性遗传学异常。LG-ESS预后惰性,5年总生存(OS)80-100%,三分之二诊断时为I-II期;HG-ESS和UUS预后差,中位OS分别为11-24个月和12-23个月,70%诊断时为III-IV期。

要点

  • LG-ESS一线治疗为不采用旋切术的全子宫切除加双侧输卵管卵巢切除术(BSO)。
  • 早期LG-ESS可选保留卵巢、保留生育治疗及辅助激素治疗±放疗。
  • HG-ESS和UUS标准治疗为不采用旋切术的全子宫切除加BSO,可选保留卵巢及辅助化疗±放疗。

核心结论

  • 本综述旨在评估恶性EST的临床、病理和生物学特征及治疗选择;LG-ESS预后惰性,HG-ESS和UUS预后差。

研究设计与样本

  • 综述,检索范围原文未报告。

主要发现

  • EST年发病率约0.30/10万女性,主要影响围绝经期或绝经后女性。
  • LG-ESS最常见遗传学改变为JAZF1-SUZ12重排,HG-ESS两大亚型分别以t(10;17)(q23,p13)易位和BCOR基因异常为特征。
  • LG-ESS通常表达雌激素和孕激素受体,而HG-ESS不表达。
  • LG-ESS的5年OS为80-100%,三分之二诊断时为I-II期;HG-ESS中位OS为11-24个月,70%诊断时为III-IV期;UUS中位OS为12-23个月,70%诊断时为III-IV期。

关键数值与推荐

  • 早期LG-ESS一线治疗:不采用旋切术的全子宫切除加BSO。
  • 选择性病例可考虑保留卵巢、保留生育治疗及辅助激素治疗±放疗。
  • 晚期或复发LG-ESS可接受手术减瘤后激素治疗,或激素治疗后手术减瘤。
  • 早期HG-ESS和UUS标准治疗:不采用旋切术的全子宫切除加BSO;可选保留卵巢及辅助化疗±放疗。
  • 晚期或复发HG-ESS可考虑手术减瘤及新辅助或辅助化疗;生物制剂和免疫治疗正在研究中。

临床怎么用

  • 早期LG-ESS采用不旋切的全子宫切除加BSO作为一线治疗。
  • 选择性LG-ESS病例可考虑保留卵巢、保留生育治疗及辅助激素治疗±放疗。
  • 晚期或复发LG-ESS可采用手术减瘤与激素治疗(顺序可互换)。
  • 早期HG-ESS和UUS采用不旋切的全子宫切除加BSO,可选保留卵巢及辅助化疗±放疗。
  • 晚期或复发HG-ESS可考虑手术减瘤及新辅助或辅助化疗。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Endometrial stromal tumors (EST) are uterine mesenchymal tumors, which histologically resemble endometrial stroma of the functioning endometrium. The majority of EST are malignant tumors classified as low-grade endometrial stromal sarcoma (LG-ESS), high-grade endometrial stromal sarcoma (HG-ESS), and undifferentiated uterine sarcoma (UUS). Overall, ESTs are rare malignancies, with an annual incidence of approximately 0.30 per 100'000 women, mainly affecting peri- or postmenopausal women. The most common genetic alteration identified in LG-ESS is the JAZF1-SUZ12 rearrangement, while t(10;17)(q23,p13) translocation and BCOR gene abnormalities characterize two major subtypes of HG-ESS. The absence of specific genetic abnormalities is the actual hallmark of UUS. Unlike HG-ESSs, LG-ESSs usually express estrogen and progesterone receptors. Total hysterectomy without morcellation and bilateral salpingo-oophorectomy (BSO) is the first-line treatment of early-stage LG-ESS. Ovarian preservation, fertility-sparing treatment, and adjuvant hormonal therapy ± radiotherapy may be an option in selected cases. In advanced or recurrent LG-ESS, surgical cytoreduction followed by hormonal treatment, or vice versa, are acceptable treatments. The standard treatment for apparently early-stage HG-ESS and UUS is total hysterectomy without morcellation with BSO. Ovarian preservation and adjuvant chemotherapy ± radiotherapy may be an option. In advanced or recurrent HG-ESS, surgical cytoreduction and neoadjuvant or adjuvant chemotherapy can be considered. Alternative treatments, including biological agents and immunotherapy, are under investigation. LG-ESSs are indolent tumor with a 5-year overall survival (OS) of 80-100% and present as stage I-II at diagnosis in two third of patients. HG-ESSs carry a poor prognosis, with a median OS ranging from 11 to 24 months, and 70% of patients are in stage III-IV at presentation. UUS median OS ranges from 12 to 23 months and, at diagnosis, 70% of patients are in stage III-IV. The aim of this review is to assess the clinical, pathological, and biological features and the therapeutic options for malignant ESTs.

来源:Gynecol Oncol,查看原文。版权归原作者所有。

引用

  1. Gadducci A, Multinu F, De Vitis LA, et al. Endometrial stromal tumors of the uterus: Epidemiology, pathological and biological features, treatment options and clinical outcomes. Gynecol Oncol. 2023. PMID: 36842409. doi:10.1016/j.ygyno.2023.02.009

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。